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INTRODUCTION 
 
Bone remodeling is a continuous and highly 
synchronized process which occurs throughout the 
lifetime of an individual. As aging progresses, the 
activities of the bone cells, including osteoclasts (OCs) 
and osteoblasts (OBs) become dysregulated, with 
osteoclast activity exceeding osteoblastic bone 
formation, leading to bone loss. Although both females 
and males experience osteoporosis in aging, post-
menopausal women suffer higher bone resorption levels 
due to low estrogen levels [1–3]. While many risk 
factors are associated with declining bone mass in 
aging, a complete understanding of the cellular 
mechanisms related to bone loss and the impact of these 
cells within the bone marrow is still lacking. 
 
A growing body of evidence suggests that 
megakaryocytes (MKs), which are platelet-producing 
cells, regulate the skeletal system by impacting the 
growth and function of both the mesenchymal-derived 
OBs and hematopoietic-derived OCs [4–15]. Many 
human conditions as wells as animal models 
demonstrate a strong link between high MK numbers 
and high bone mass [6, 16–20]. Mice with elevated MK 
numbers exhibit up to a 3-fold increase in bone mass in 
vivo, which is attributed in part to MK-stimulated OB 
proliferation [6, 11, 15, 20]. However, the MK-mediated 
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Megakaryocytes (MKs) support bone formation by stimulating osteoblasts (OBs) and inhibiting osteoclasts 
(OCs). Aging results in higher bone resorption, leading to bone loss. Whereas previous studies showed the 
effects of aging on MK-mediated bone formation, the effects of aging on MK-mediated OC formation is 
poorly understood. Here we examined the effect of thrombopoietin (TPO) and MK-derived conditioned 
media (CM) from young (3-4 months) and aged (22-25 months) mice on OC precursors. Our findings showed 
that aging significantly increased OC formation in vitro. Moreover, the expression of the TPO receptor, Mpl, 
and circulating TPO levels were elevated in the bone marrow cavity. We previously showed that MKs from 
young mice secrete factors that inhibit OC differentiation. However, rather than inhibiting OC development, 
we found that MKs from aged mice promote OC formation. Interestingly, these age-related changes in MK 
functionality were only observed using female MKs, potentially implicating the sex steroid, estrogen, in 
signaling. Further, RANKL expression was highly elevated in aged MKs suggesting MK-derived RANKL 
signaling may promote osteoclastogenesis in aging. Taken together, these data suggest that modulation  
in TPO-Mpl expression in bone marrow and age-related changes in the MK secretome promote 
osteoclastogenesis to impact skeletal aging. 
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stimulation of OB proliferation and bone formation is 
impaired with aging, despite the marked increase in MK 
number in vivo, suggesting that aged MKs have 
decreased capacity to stimulate bone formation [21]. 
 
In contrast to stimulating OB activity, MKs are known 
to negatively impact OC differentiation. MKs from 
human cord blood or murine fetal livers significantly 
inhibit OC formation in vitro [5, 11, 14]. However, the 
mechanisms and secreted factors that control the effects 
of MKs on osteoclastogenesis are not entirely clear. 
MKs are also known to express estrogen receptors, and 
treatment with estrogen impacts MK function, including 
the secretion of OPG and RANKL, which are known to 
regulate OC number [4, 19, 22], but whether these 
factors are changed with aging, resulting in increased 
OC formation is unknown. Therefore, in the current 
study, we investigated the influence of aging on MK-




Increased osteoclastogenesis by CD45+F4/80+ 
macrophages from aged mice 
 
We first confirmed that OC progenitors from aged 
C57BL/6J mice have increased potential to undergo 
osteoclastogenesis compared to those from young mice. 
For these studies, we used CD45+F4/80+ macrophages 
isolated by fluorescence activated cell sorting (FACS) 
of bone marrow from aged (22-25 months) and young 
(3-4 months) mice. We previously reported that this 
subpopulation are also CD11b+, which is a classical 
osteoclast marker [23]. In vitro osteoclastogenesis was 
performed by culturing these cells with the necessary 
OC cytokines, RANKL (80 ng/ml) and M-CSF (20 
ng/ml). Similar to previous reports [24], the number of 
TRAP+ multinucleated osteoclasts generated from aged 
CD45+F4/80+ macrophages was 3.2-fold higher than 
that generated from young CD45+F4/80+ macrophages 
(***p<0.001) (Figure 1A, 1B). However, aging did not 
appear to affect the frequency of the CD45+F4/80+ 
macrophage subpopulation in the bone marrow of 
young versus aged mice (Figure 1C). 
 
Megakaryocytes and TPO are increased in aged 
bone marrow 
 
Given that MKs occupy a strategic position within the 
bone marrow cavity and are known to regulate OC 
formation [11, 14, 19], we examined if aging is 
correlated with changes in the number of bone marrow 
MKs in male and female mice. We compared the total 
number of MKs (CD45+CD41+ cells) in the bone 
marrow of aged and young C57BL/6J mice by flow 
cytometry. Interestingly, we found approximately a 2.1-
fold increase in the number of MKs in flushed bone 
marrow from female aged mice, compared to female 
young mice (Figure 2A). A trend towards increased MK 
number in male aged mice was also observed but did 
not reach statistical significance. 
 
MK proliferation and differentiation are regulated by 
the growth factor, thrombopoietin (TPO), which acts  
via its specific receptor Mpl [16, 25, 26]. Therefore,  




Figure 1. Aging increases OC formation from sorted CD45+F4/80+ bone marrow macrophages. Similar numbers of sorted 
CD45+F4/80+ macrophages from young and aged C57BL/6J mice were cultured in the presence of RANKL (80 ng/ml) and M-CSF (20 ng/ml). 
Growth media was changed every second day for 5-7 days until mature, multinucleated OCs (>3 nuclei) were formed. (A) Images of TRAP+ 
OCs generated. Scale bar is 100 µm. (B) The number of TRAP+ OCs formed in each well was quantified, showing that more OCs were 
generated from aged CD45+F4/80+ macrophages compared to young macrophages. Four independent experiments gave similar results, and 
a representative experiment is shown. Graphs are mean ± SD with ***p<0.001 (N=4/group). (C) Frequency of CD45+F4/80+ macrophage (%) 
in bone marrow cells isolated from young and aged C57BL/6J mice (males and females combined). Data are mean ± SD of four independent 
experiments (p=0.08, ns indicates non-significant). 
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versus young mice. Interestingly, aged MKs express 
significantly higher Mpl levels than young MKs  
(Figure 2B). Together with the increase in bone marrow 
MK numbers in aged mice (Figure 2A), these findings 
suggest that the increase in MK number with aging may 
be the result of increased megakaryopoiesis, which is 
supported by our previous studies [21]. 
 
We further examined the mechanism leading to the 
increase in MK number in aged male and female mice 
by quantifying extracellular TPO levels. We first 
quantified TPO in serum from aged versus young mice 
using a specific ELISA. In addition, given that bone 
marrow MKs are likely to be influenced by changes in 
local paracrine factors, we also isolated bone marrow 
supernatant from hindlimbs of young and aged mice. 
However, due to the small amount of bone marrow 
supernatant recovered, male and female mice were 
combined. As shown in Figure 3A, TPO was 
significantly lower in the serum of aged mice versus 
young mice for both female and male cohorts. In 
contrast, TPO levels in bone marrow supernatant  
were significantly higher in aged mice compared  
to young mice (Figure 3B). These findings may  
suggest that increased TPO in the bone marrow, 
combined with increased Mpl expression in MKs, may 





Figure 2. Aging increases bone marrow MK number. (A) Flow cytometry was used to determine the total number of CD45+CD41+ MKs 
in the bone marrow of young and aged C57BL/6J female and male mice. The data are presented as mean ± SD of four independent 
experiments with *p<0.05 (N=4/group). (B) Bone marrow CD45+CD41+ MKs were isolated by FACS from young and aged mice (males and 
females were combined) and used for real-time PCR analysis of relative Mpl mRNA expression between groups. The Ct cycle range was 




Figure 3. Changes in TPO levels in young and aged mice. (A) TPO concentration was measured by ELISA in serum from young and 
aged, male and female C57BL/6J mice. Serum TPO was significantly reduced in aged female and male mice compared to sex-matched young 
mice. The data are presented as mean ± SD (*p<0.05, **p<0.01, N=9-10/group). (B) Bone marrow supernatant was collected from young and 
aged femur and tibia (male and female mice were combined) and used to determine TPO concentrations by ELISA. The data are presented as 
mean ± SD (*p<0.05; N=5/group). 
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Direct effects of TPO on osteoclastogenesis 
 
In addition to MKs, Mpl is expressed on several other 
cell types within the bone marrow. For example, our 
previous findings confirmed that OC progenitors from 6-
8 week-old C57BL/6J mice express Mpl, and robustly 
respond to recombinant TPO, resulting in an increase in 
OC formation [27, 28]. Therefore, we examined if 
osteoclastogenesis associated with aging is affected by 
differences in Mpl-TPO signaling. As Mpl is expressed 
on several cell types within the bone marrow cavity we 
isolated CD45+F4/80+ macrophages by FACS from 
young and aged mice, and analyzed for Mpl expression 
by real-time quantitative PCR. As shown in Figure 4A, 
CD45+F4/80+ macrophages from aged mice express 
significantly higher Mpl mRNA than young CD45+ 
F4/80+ macrophages, suggesting they may be more 
responsive to TPO. To test this, we examined possible 
differential responses to TPO-induced osteoclastogenesis. 
CD45+F4/80+ macrophages were isolated from the bone 
marrow of young and aged mice and then cultured  
in the presence of M-CSF and RANKL, supplemented 
without or with 100 ng/ml TPO. The concentration of 
TPO used was previously demonstrated to induce 
osteoclastogenesis in macrophage cultures [28]. As 
shown in Figures 4B, 4C, TPO stimulated a significant 
increase in OC number in both young and aged 
CD45+F4/80+ macrophages, suggesting that TPO-
induced osteoclastogenesis is independent of aging. 
 
Aging impairs the ability of megakaryocytes to 
inhibit osteoclast differentiation 
 
The studies above revealed an increase in bone marrow 
TPO levels in aged mice compared to young mice, and 
that TPO increases OC formation in CD45+F4/80+ 
macrophages isolated from both young and aged mice 
(Figures 3, 4). Moreover, we observed an increase in 
MK number in aged bone marrow (Figure 2). However, 
we and others also showed that MKs derived from fetal 
livers (males and females were not separated) or cord 
blood secrete factors that inhibit OC formation [11, 14, 
19]. To investigate this apparent contradiction, we 
examined whether MKs from aged mice have altered 
functionality with respect to osteoclastogenesis. 
 
MKs were isolated from young and aged, male and 
female mice, and used to prepare conditioned media 
(CM) as described in the methods [14]. Unsorted bone 
marrow macrophages or BMMs (OC-progenitors) from 
the bone marrow of 6-10 week-old mice were then 
cultured in media containing 25% (v/v) MK CM plus 
RANKL (80 ng/ml) and M-CSF (20 ng/ml). Control 
media containing only RANKL and M-CSF was also 
used. Figures 5A, 5B show that OC formation was lower 
in cultures containing CM from female young MKs 
compared to control media, confirming that MKs inhibit 
osteoclastogenesis as we reported previously [14]. In 
contrast, cultures containing female aged MK CM 
produced significantly more OCs than young female MK 
CM (p<0.0001) or control media (p<0.01). On the other 
hand, as illustrated in Figure 5C, male MK CM showed 
no significant effect on OC formation whether or not 
MKs were derived from young or aged mice (p>0.05). 
 
Since RANKL and M-CSF are required for in vitro 
osteoclastogenesis assays, we also conducted studies in 
media containing 25% (v/v) MK CM plus one-third 
reduced concentrations of RANKL and/or M-CSF 




Figure 4. TPO stimulates OC formation. (A) FACS sorted CD45+F4/80+ macrophages from young and aged mice were subject to real-time 
PCR to assess the relative mRNA expression of Mpl. The Ct cycle range was 34.06–35.15. The data shown are mean ± SD (*p<0.05). (B, C) 
FACS sorted CD45+F4/80+ macrophages were cultured with 20 ng/ml M-CSF and 80 ng/ml RANKL in the presence or absence of recombinant 
human TPO (100 ng/ml). Growth media was changed every second day for 5–7 days until mature, multinucleated OCs (>3 nuclei) were 
formed. Mature OCs were fixed and TRAP+ OCs were counted. The data are presented as mean ± SD of four (female) and two (male) 
independent experiments (*p<0.05, ***p<0.001; N=3/group). 
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expected, a reduction in overall OC numbers was 
observed in culture media (without CM) using the sub-
optimal RANKL and M-CSF conditions as shown in 
Figure 5F. 
 
Modulation of RANKL in megakaryocytes during 
aging 
 
The importance of RANKL and M-CSF for 
osteoclastogenesis is well established [29, 30]. OC 
numbers are also affected by osteoprotegerin (OPG) 
which blocks the ability of RANKL to bind to the 
RANK receptor on OC precursors [31]. Furthermore, as 
aging progresses, the level of RANKL in whole bone 
and in cultured bone marrow cells from both humans 
and rodents gradually increases [32]. Therefore, we 
examined whether MKs from young and aged mice 
express different mRNA levels of these cytokines. As 
shown in Figure 6A, 6B, MKs from aged female or 
male mice showed reduced expression of M-CSF 
(Figure 6A) and OPG (Figure 6B) compared to sex-
matched young mice. However, RANKL mRNA 
(Figure 6C) was markedly higher in MKs from aged 
mice compared to young mice, for both females and 
males. Moreover, the ratio of RANKL/OPG (Figure 
6D) was increased in MKs from aged mice, suggesting 
increased potential to induce osteoclastogenesis 
compared to MKs from young mice. We next confirmed 
whether MKs secrete RANKL, as determined by 
specific ELISA. Consistent with an increase in RANKL 
mRNA, we observed that MKs from aged female mice 
secrete RANKL at significantly higher levels than MKs 
from young female mice, young male mice, as well as 
aged male mice (Figure 6E). Together, these data 
suggest that MKs from aged female mice may stimulate 




Increases in OC activity result in bone loss as is seen 
with menopause and aging. MKs can regulate bone 




Figure 5. Effect of MK conditioned media on OC formation. (A–E) Conditioned medium (CM) was prepared from MKs isolated from 
young and aged, female and male mice. (A–C) Unsorted BMMs from mice (6-10 weeks) were cultured in media containing 25% (v/v) MK CM 
plus RANKL (80 ng/ml) and M-CSF (20 ng/ml). The control media was prepared without MKs. (A) Micrographs showing mature OCs. Scale 
bar is 50 µm. (B, C) The number of TRAP+ multinucleated OC (>3 nuclei) was quantified. The data show that MK CM from young female 
mice inhibits OC formation compared to control and aged female MK CM. The data are presented as mean ± SD of three experiments 
(****p<0.0001 compared to the control group). No significant difference in OC formation was observed between male groups. (D, E) 
Unsorted BMMs from mice (6-10 weeks) were differentiated into mature OCs in media containing 25% MK CM plus normal or reduced 
RANKL (80 or 26.6 ng/ml, respectively) and M-CSF (6.6 or 20 ng/ml, respectively). Mature OCs were fixed and TRAP+ OCs were counted. (F) 
Comparison of OCs formed in control media (no MK CM) with normal or reduced RANKL and M-CSF. Three independent experiments 
showed similar results and a representative figure is shown. The data are presented as mean ± SD (**p<0.01, ***p<0.001, ****p<0.0001; 
N= 3/group). P-values were calculated by one-way ANOVA followed by Tukey’s post-hoc test. 
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resorption. In several mouse models with increased 
bone marrow megakaryopoiesis, a significant increase 
in bone volume, due to increases in bone formation, has 
been reported; adult mice less than 9 months of age 
were used for these studies [6, 15, 20, 21, 33–37]. Our 
group [14] and others [5] have also shown that MKs 
from young mice or human umbilical cord blood, 
respectively, secrete factor(s) that inhibit OC formation 
up to 10-fold. These studies suggest that in young mice, 
MKs contribute to bone gain through both increased 
bone formation and decreased osteoclast resorption. 
However, whether this is different between males and 
females has not been investigated. Moreover, the 
signaling factors secreted by young MKs versus aged 
MKs that differentially regulate OC formation during 
aging remain to be identified. As it has become 
increasingly clear that aging results in the dysregulation 
of a number of cells and systems, we explored how 
aging affects the ability of MKs to inhibit OC formation 
and the role of TPO, the principal MK-growth factor, on 
OC formation. 
 
In the current study, we found that MK CM from young 
female mice, but not young male mice inhibited OC 
formation (Figure 5). In contrast, MK CM from aged 
female mice led to an increase in OC formation. 
Although in the current study we did not investigate 
direct coculture of aged MKs with OC progenitors, we 
previously reported that OC formation is inhibited by 
both direct contact with young female MKs and by 
young MK CM [14], and we therefore expect similar 
findings using aged MKs. The increase in MK-mediated 
OC formation in aging may be due to an increase in pro-
osteoclastic factors, including RANKL. We found that 
RANKL mRNA expression was markedly elevated in 




Figure 6. Expression of key OC factors in MKs from young and aged mice. (A–D) MKs were prepared from the bone marrow of 
young and aged, male and female mice using a BSA gradient and used for mRNA expression analyses by real-time PCR. (A) M-CSF mRNA (Ct 
cycle range was 25.2–30.12). (B) OPG mRNA (Ct range 35.09–39.53). (C) RANKL mRNA (Ct range 28.6–35.5). (D) The RANKL/OPG ratio was 
calculated for young and aged, male and female MKs (N=4-5/group). (E) RANKL concentrations in MK CM was quantified by ELISA. MK CM 
from aged females was significantly higher than MK CM from young females. P-values were calculated by one-way ANOVA followed by 
Tukey’s post-hoc test and the data are presented as mean ± SD. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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However, only CM from aged female MKs showed 
significantly elevated RANKL protein levels, compared 
with sex-matched young mice. These data not only 
suggest that MKs from aged female mice may stimulate 
OC formation through increased RANKL secretion, but 
that RANKL mRNA translation, secretion, or protein 
stability may be different in aged male MKs versus 
aged female MKs. Together, our data indicate sexual 
dimorphism in the regulation of RANKL and the age-
associated osteoclastogenic effects of MKs. 
 
In post-menopausal women treated with estrogen, a 
correlation between increased MK numbers and high 
bone mass has been previously reported [19, 22]. 
Further, estradiol treatment of CD61+ MK lineage cells 
isolated from human cord blood cells was reported to 
significantly increase OPG expression, and 
simultaneously reduce RANKL expression [38]. 
Together with our current findings, it is possible that in 
conditions of reduced estrogen levels as occurs in aging, 
MKs may express high RANKL levels, which would 
support increased osteoclastogenesis. These finding are 
important since denosumab, an anti-RANKL therapy, is 
currently used for the treatment of osteoporosis [39], 
and our findings suggest that MKs are an important 
cellular source of RANKL that may contribute to bone 
loss in aging. 
 
An alternative mechanism by which aged MKs increase 
OC formation by could be the loss of a yet-to-be 
determined inhibitory factor(s). We previously 
published that OC formation was similar between MKs 
from young OPG-deficient mice and young wild-type 
mice [14]. Based on these previous findings, it is 
unlikely that OPG is responsible for the inhibition of 
OC formation observed by MKs from young female 
mice in the current study (Figure 5). However, the 
decline in secreted OPG in aged MKs may, contribute 
to the increase in OC formation by increasing the 
RANKL/OPG ratio as we observed (Figure 6). 
 
Bone loss in aging is generally associated with an 
overall increase in the number of bone resorbing OCs. 
This could be due to an increase in the number of OC 
progenitors such as BMMs, or increased proliferation of 
BMMs. Accelerated osteoclastogenesis or increased/ 
decreased expression of OC-regulating factors within 
the bone marrow environment may also be involved. 
Our studies reveal that sorted CD45+F4/80+ 
macrophages (OC progenitors) from aged mice show 
increased capacity to undergo osteoclastogenesis, 
compared with those from young mice (Figure 1). We 
also found that aging increases the number of MKs 
within the bone marrow cavity (Figure 2). The increase 
in both MK numbers and OC formation with aging may 
be influenced by hematopoietic skewing to the myeloid 
lineage, which is known to occur with aging [40, 41]. It 
was reported that aged human OC progenitors express 
higher RANK mRNA, which may make them more 
susceptible to RANKL stimulation [42]. Other groups 
have also shown that RANKL levels in whole bone and 
cultured bone marrow cells gradually increase with age 
in both humans and rodents [43, 44]. Combined with 
these reports, our findings that aging increases MK-
derived RANKL expression and secretion (Figure 6) 
suggest that increased RANKL signaling is likely a key 
driver of the increase in OC formation by MKs in aging. 
 
As TPO is the main growth factor for MKs, we 
examined TPO levels in sera and bone marrow 
supernatant of young and aged mice (Figure 3). An 
unexpected reduction in serum TPO was observed in 
aged mice compared to young controls. Although it is 
currently unclear why systemic TPO levels decline with 
aging, some possibilities may include an age-associated 
decline in TPO production by primary (e.g., liver) or 
secondary (e.g., kidney) tissue sources, or that TPO is 
sequestered away from the circulation. Alternatively, 
the reduction in serum TPO could be explained by the 
higher numbers of platelets [21], which can bind 
circulating TPO, a well-documented phenomenon [45]. 
Despite the reduction in circulating TPO, we found 
increased TPO concentrations in the bone marrow 
supernatant of aged mice compared to young mice 
(Figure 3). As demonstrated here and in our previous 
publications [28], recombinant TPO (without the 
presence of MKs) increased the number of mature 
TRAP+ multinucleated OCs generated from young and 
aged OC progenitors. By contrast, Wakikawa et al. [46] 
used whole bone marrow cultures containing both OC 
progenitors and MKs/MK progenitors and found that 
TPO inhibited OC development, likely owing to the 
MK-mediated inhibition of OC formation. Our current 
studies also confirm that the TPO receptor, Mpl (also 
known as CD110), is more highly expressed on OC 
progenitors from aged mice, compared to young mice 
(Figure 4A). Further, we reported that Mpl is required 
for TPO to enhance OC formation in vitro [28]. 
However, it is unknown whether in vivo the higher level 
of TPO in aged bone marrow preferentially acts on Mpl 
on MKs to increase MK number (Figure 2), which in 
turn affects OC formation, or alternatively whether TPO 
acts directly on OC-progenitors to increase OC 
formation (Figure 4). 
 
In summary, our findings demonstrate that Mpl, the 
receptor for TPO [47], is upregulated in OC-progenitor 
cells in aging. Our studies also demonstrate that 
BMMs from young and aged mice respond similarly to 
TPO, leading to increased OC formation. Moreover, 
we found that aged bone marrow contains more OCs, 
MKs, and TPO compared to young mice; and that 
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MKs from aged female mice secrete more RANKL 
than young female, young male, or aged male mice. As 
summarized in Figure 7, these findings support both 
the direct effects of TPO on OC formation, as well as 
TPO-driven increases in MK number and RANKL 
secretion to promote OC formation and decrease bone 




Figure 7. Model showing OC stimulation by TPO and MKs 
in aging. The schema illustrates that aging increases MK number 
and alters MK-secreted factors, including RANKL, which together 
promote osteoclastogenesis. In addition, elevated TPO in the 
bone marrow cavity promotes direct and MK-mediated effects on 
OC formation in aged mice. 
 
MATERIALS AND METHODS 
 
Experimental animals and mouse strains 
 
Animals were maintained, bred, and handled following 
protocols approved by the Indiana University 
Institutional Animal Care and Use Committee (IACUC) 
and in accordance with the NIH Guidelines for the care 
and use of laboratory animals. In our studies, young 
(~3-4 month-old) C57BL/6J mice were bred and housed 
at the Indiana University School of Medicine. Aged 
(~23-25 month-old) C57BL/6J mice were provided by 
the National Institute of Aging of the National Institutes 
of Health. 
 
Preparation of adult bone marrow-derived 
megakaryocytes 
 
Single cell suspensions of bone marrow from long 
bones (femur and tibiae) were obtained. Cells were 
cultured in Dulbecco Modified Eagle Medium 
(DMEM, Grand island, NY, USA) containing 5%  
fetal bovine serum (FBS, Hyclone, GE Healthcare  
Life Sciences, Pittsburgh, PA), 1000 U/ml 
Penicillin/Streptomycin (Invitrogen, Waltham, MA), 
and supplemented with 1% (v/v) media collected from 
a murine TPO-secreting fibroblast cell line [14, 18]. 
MKs were isolated after ~7–10 days using a one-step 
BSA gradient to separate them from lymphocytes and 
other cells. This results in approximately a 90–95% 
pure MK population [15, 48]. 
 
Preparation of megakaryocyte conditioned media 
 
MK CM was prepared as previously described [11, 14]. 
In brief, 1 x 106 MKs/ml were cultured in α-MEM 
(Grand island, NY, USA) containing no serum and no 
phenol red. After three days CM was collected and 
stored at -80°C until use. For the current study we used 
25% CM (v/v) for OC development assays as described 
below. 
 
Osteoclast differentiation assays 
 
Femurs and tibiae were dissected from mice, the 
epiphyses were removed, and the marrow was flushed 
with a 27-gauge needle and syringe containing α-MEM 
with 10% FBS. Bone marrow cells were suspended into 
single cells and washed twice prior to use. Bone marrow 
cells were then prepared using previously described 
protocols [28]. Briefly whole bone marrow was plated 
into 35mm tissue culture dishes in α-MEM 
supplemented with 10% FBS. After 24 hours, the non-
adherent cells were collected. These unsorted 
monocyte/myeloid progenitors, which we termed bone 
marrow macrophages (BMMs), were used for 
osteoclastogenesis assays as described below. 
Alternatively, bone marrow cells were FACS sorted to 
isolate CD45+F4/80+ macrophages, which were then 
used in osteoclastogenesis assays as indicated. 
 
For osteoclastogenesis assays with MK CM, BMMs 
from young mice 6-10 weeks of age (males and females 
combined), were seeded at 0.7-1.5 x 105 cells in 96-well 
plates and cultured in α-MEM supplemented with 10% 
FBS and 20 ng/ml M-CSF and 80 ng/ml RANKL 
(PeproTech Inc., Rocky Hill, NJ). In some studies, sub-
optimal concentrations of M-CSF (6.6 ng/ml) and 
RANKL (26.6 ng/ml) were used. MK CM at 25% 
vol/vol was added to the culture media. 
 
For osteoclastogenesis assays involving TPO, FACS 
sorted CD45+F4/80+ macrophages were cultured at 7–9 
x 104 cells in 96-well plates in α-MEM supplemented 
with 10% FBS and 20 ng/ml M-CSF and 80 ng/ml 
RANKL plus 100 ng/ml recombinant human TPO 
(PeproTech). For all studies, growth media was changed 
every second day for 5-7 days until mature, 
multinucleated OCs (>3 nuclei) were formed. Cells 
were fixed and stained for tartrate resistant acidic 
phosphatase (TRAP, Sigma-Aldrich, St. Louis, USA). 
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Images were acquired at 10X magnification using the 
Image pro plus 7.0 software on Leica DMI4000 
equipped with digital camera. All experiments were 
repeated at least 3 times. 
 
Flow cytometry and cell sorting 
 
FACS-sorted CD45+F4/80+ macrophages were 
prepared as previously described [6]. Briefly murine 
bone marrow mononuclear cells were blocked with 
TruStain FcX (Bio-legend, San Diego, CA) for 15 
minutes at 4°C and stained with anit-CD45 (clone: 30-
F11) and anti-F4/80 (clone: BM8) (Bio-legend) 
antibodies for 30 minutes at 4°C. Cells were washed 
with wash buffer (1% FBS in PBS and 1% Pen-Strep). 
CD45+F4/80+ macrophages were sorted using BD 
FACSAria and used for osteoclastogenesis assays as 
indicated above. For MKs, bone marrow cells were 
prepared and stained as above except anti-CD41 
antibody (clone: MWReg30; Bio-legend) was used 
instead of the F4/80 antibody. MKs were CD45+CD41+ 
cells. Cells were acquired using the BD LSRFortessa 
(BD Biosciences. San Jose, CA) and analyzed by 
FlowJo software (BD Biosciences). 
 
RNA extraction and real-time PCR 
 
Total RNA from bone marrow derived MKs or BMMs 
was isolated using RNeasy Plus Micro Kit (Qiagen, 
Valencia, CA) and used to prepare complementary 
DNA (cDNA) using the SuperScript™ IV VILO™ 
Master Mix (ThermoFisher Scientific). mRNA 
expression levels for each gene were quantified by 
quantitative real-time PCR using the CFX96 real time 
system (Bio-Rad, Hercules, CA, USA) with the Power 
SYBR™ Green PCR Master Mix (ThermoFisher 
Scientific). Gene expression levels were normalized to 
the corresponding GAPDH gene expression. All 
samples were run in duplicate, and at least 3 separate 
biologic replicates were analyzed. The Ct cycle number 
for each gene is shown in the figure legends. 
 











Detection of RANKL in megakaryocyte conditioned 
media 
 
MK CM was collected as described above, and stored in 
aliquots at -80°C. Undiluted CM was assayed for 
RANKL using a specific ELISA kit (R&D Systems, 
Minneapolis, MN) as per the manufacturer’s 
instructions. 
 
Measurement of TPO in serum and bone marrow 
supernatant 
 
Whole blood was collected from mice at necropsy by 
cardiac puncture, and serum was separated and stored at 
-80°C until assayed. Bone marrow from the hindlimbs 
of mice was removed through centrifugation, and the 
supernatant, devoid of bone marrow cells, was collected 
and stored at -80°C until assayed. The serum and bone 
marrow supernatant samples were diluted as necessary 
(up to 1:4) and assayed for TPO concentration using  
the Mouse Thrombopoietin Quantikine ELISA kit 





Graphpad prism software (Graphpad Software, Inc. La 
Jolla, CA, USA) was used for statistical analyses. Unless 
otherwise specified, an unpaired two-tailed Student’s t-
test was applied for comparisons between two groups. 
The statistical significance of differences among groups 
was assessed using analysis of variance (ANOVA) with a 
Tukey post-hoc multiple comparisons test. All data are 
presented as the mean ± standard deviation (SD). P<0.05 
was considered significant. All independent experiments 




MK: megakaryocyte; OB: osteoblast; OC: osteoclast; 
TPO: thrombopoietin; M-CSF: macrophage colony 
stimulating factor; RANKL: receptor activator of 
nuclear factor kappa-Β ligand; OPG: osteoprotegerin; 
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